查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
乳腺癌液体活检市场规模、份额和趋势分析报告：循环生物标誌物（循环肿瘤细胞、循环无细胞 DNA、细胞外囊泡），按应用、地区、细分市场预测，2022-2030 年
市场调查报告书
商品编码
1170885

乳腺癌液体活检市场规模、份额和趋势分析报告：循环生物标誌物（循环肿瘤细胞、循环无细胞 DNA、细胞外囊泡），按应用、地区、细分市场预测，2022-2030 年

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report By Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), By Application, By Region, And Segment Forecasts, 2022 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

乳腺癌液体活检市场增长及趋势

据Grandview Research最新报告显示，2022-2030年全球乳腺癌液体活检市场预计将以22.7%的复合年增长率增长，到2030年将达到17亿美元。这种增长的背后是对非侵入性技术的日益偏好、早期诊断和治疗意识的提高以及乳腺癌患病率的增加。例如，据世界卫生组织称，到 2020 年，乳腺癌将夺去 685,000 名妇女的生命，并影响全球 230 万名妇女。液体活检已被提议作为乳腺癌早期检测的突破性技术，促进其采用并刺激增长。

随着乳腺癌发病率的增加，人们迫切需要提供合适的诊断工具，以实现癌症的早期发现和早期治疗。为了满足日益增长的需求，诊断试剂领域的研究和开发正在加紧进行。例如，2022 年 6 月，BioFluidica 研究结果表明，HER2 阳性乳腺癌患者在接受 HER2 定向定制治疗时具有成功率。随着相关领域的发展，液体活检的临床相关性越来越广为人知。进一步的介入性临床试验和构建适当结合循环生物标誌物的算法对于广泛采用这些技术是必要的。

正在进行的心血管生物标誌物研究中的技术突破导致了用于识别非血液恶性肿瘤的微创技术的发展。与传统的肿瘤活检相比，液体活检被认为是实时患者监测的一种有前途的选择。例如，2022 年 4 月，Epic Science 将 DefineMBC 添加到其 CLIA 实验室组合中，DefineMBC 是一种基于液体活检技术的血液检测，用于诊断转移性乳腺癌。

此外，市场上的主要参与者正专注于扩展和推出可用于广泛应用的产品。例如，2022 年 6 月，NeoGenomics 的子公司 Inivata Limited 宣布了 RaDaR 分析的新数据，用于分析人类表皮生长因子受体 2 (HER2) 阴性高危患者的微小残留病 (MRD) 和復发。宣布。

乳腺癌液体活检市场报告亮点

2021年，循环肿瘤细胞领域将占据压倒性的收入份额，因为CTC在癌症检测中的高效性和准确性

由于在早期癌症诊断中越来越多地采用液体活检以及对提供有效治疗的需求不断增长，预计早期检测部分在预测期内将以最快的复合年增长率增长。

治疗选择是 2021 年创收最高的部分，因为有许多产品可以帮助治疗选择

由于患病率增加、医疗基础设施改善和人口增长，亚太地区预计在预测期内增长最快。

目录

第一章 调查方法和范围

  • 市场细分
  • 调查方法
  • 信息采购
    • 购买的数据库
    • 次要信息
    • 初步调查
    • 初步调查详情
  • 信息或数据分析
    • 数据分析模型
  • 市场製定和验证
  • 型号详情
    • 商品流向分析
      • 方法一：商品流动方法
      • 方法 2：国家——使用自下而上的方法进行智能市场估算
  • 全球市场：复合年增长率计算
  • 调查假设
  • 二级信息列表
  • 主要信息列表
  • 目的
  • 缩略语表

第二章执行摘要

  • 市场概况

3 乳腺癌液体活检市场变量、趋势和范围

  • 乳腺癌液体活检市场谱系展望
    • 母公司市场展望
    • 辅助市场展望 - 体外诊断 (Ivd) 市场
  • 绘製渗透率和增长前景
  • 市场动态
  • 市场驱动力分析
    • 乳腺癌患病率增加
    • 在癌症诊断中越来越多地采用液体活检
    • 需要早期诊断和治疗
  • 市场约束因素分析
    • 与乳腺癌液体活检相关的高成本
    • 监管和报销障碍
  • 按因素（政治和法律、经济、技术）的 SWOT 分析
  • 波特五力分析

第 4 章循环生物标誌物的乳腺癌液体活检市场细分分析，2018-2030（百万美元）

  • 乳腺癌液体活检市场：循环生物标誌物的变化分析
    • 循环肿瘤细胞 (Ctcs)
    • 循环无细胞 DNA (Cfdna)
    • 细胞外囊泡 (Ev)
    • 其他循环生物标誌物

第 5 章乳腺癌液体活检市场-细分分析，按应用，2018-2030 年（百万美元）

  • 乳腺癌液体活检市场：应用差异分析
    • 早期检测/筛查
    • 诊断
    • 治疗选择
    • 监控

6. 2018-2030 年按地区分列的乳腺癌液体活检市场细分分析（百万美元）

  • 乳腺癌液体活检市场：区域差异分析
  • 北美
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 意大利
      • 2018-2030 年意大利乳腺癌液体活检市场（百万美元）
    • 西班牙
      • 2018-2030 年西班牙乳腺癌液体活检市场（百万美元）
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳大利亚
      • 2018-2030 年澳大利亚乳腺癌液体活检市场（百万美元）
    • 韩国
      • 2018-2030 年韩国乳腺癌液体活检市场（百万美元）
  • 拉丁美洲
    • 拉丁美洲乳腺癌液体活检市场，2018-2030（百万美元）
    • 巴西
      • 2018-2030 年巴西乳腺癌液体活检市场（百万美元）
    • 墨西哥
      • 2018-2030 年墨西哥乳腺癌液体活检市场（百万美元）
    • 阿根廷
      • 阿根廷乳腺癌液体活检市场，2018-2030（百万美元）
  • 马雷
    • Mea 乳腺癌液体活检市场，2018-2030（百万美元）
    • 南非
      • 2018-2030 年南非乳腺癌液体活检市场（百万美元）
    • 沙特阿拉伯
      • 沙特阿拉伯乳腺癌液体活检市场，2018-2030（百万美元）
    • 阿拉伯联合酋长国
      • 阿拉伯联合酋长国乳腺癌液体活检市场，2018-2030 年（百万美元）

7 乳腺癌液体活检市场：竞争分析

  • 主要市场进入者的最新发展和影响分析
    • 安索夫矩阵
    • 重大交易及战略联盟分析
      • 市场拓展
      • 产品发布会
      • 获得
      • 伙伴关係和协作
  • 公司分类
    • 创新者
    • 市场领导者
  • 供应商情况
    • 主要经销商及渠道合作伙伴名单
    • 主要客户
    • 2021 年主要参与者的市场份额分析
  • 上市公司
    • 公司市场分析
    • 热图分析
    • 区域网络图
    • 竞争仪錶盘分析
      • 市场差异化因素
  • 民营企业
    • 主要初创企业名单
    • 热图分析
    • 区域网络图

第八章公司简介

  • The Menarini Group
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • NeoGenomics Laboratories
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • F. Hoffmann-La Roche Ltd.,
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Myriad Genetics, Inc.
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Thermo Fisher Scientific, Inc.
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • QIAGEN
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Biocept, Inc.
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Sysmex Corporation
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Fluxion Biosciences, Inc.
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
  • Epic Sciences, Inc.
    • 公司简介
    • 财务绩效
    • 产品基准
    • 战略举措
Product Code: GVR-4-68039-991-9

Breast Cancer Liquid Biopsy Market Growth & Trends:

The global breast cancer liquid biopsy market size is expected to reach USD 1.7 billion by 2030, expandingat a CAGR of 22.7% from 2022 to 2030, according to a new report by Grand View Research, Inc. The growth is attributed to the rising preference for non-invasive methods, rising awareness of early diagnosis and treatment, and rising prevalence of breast cancer. For instance, according to WHO, in 2020, globally, 685,000 women lost their lives to breast cancer, and 2.3 million women were affected by it. Liquid biopsies have been suggested as a revolutionary technique for the early identification of breast cancer, which boosts its adoption and spurs growth.

With the increasing prevalence of breast cancer, there is a high demand to provide proper diagnostics tools for detecting cancer at an early stage and early treatment. There has been increasing R&D in the field of diagnostics to cater to the rising demand. For instance, in June 2022, according to study findings from BioFluidica, patients with HER2-positive breast cancer had success rates while receiving tailored HER2-directed therapy.The clinical significance of liquid biopsy is becoming more well-known as a result of ongoing developments in related fields. Additional interventional clinical trials and the creation of an algorithm to properly combine circulating biomarkers are required to make these technologies widely accessible.

A less intrusive technique for identifying non-hematological malignancies has been developed as a result of technological breakthroughs in continuing research on circulating biomarkers. Compared to traditional tumor biopsy, liquid biopsy is thought to be a promising option for patient monitoring in real time. For instance, in April 2022, Epic Sciences, Inc., launched DefineMBC, a blood test based on liquid biopsy technology for the diagnosis of metastatic breast cancer to its CLIA laboratory portfolio.

Furthermore, key players operating in the market are focusing on expanding and launching products that can be used for a wide range of applications. For instance, in June 2022, NeoGenomics's subsidiary Inivata Limited announced new data for RaDaR assay for the analysis of human epidermal growth factor receptor 2 (HER2)-negative, high-risk patients with minimal residual disease (MRD) and recurrence.

Breast Cancer Liquid Biopsy Market Report Highlights:

  • In 2021, the circulating tumor cells segment held a dominant revenue share owing to the effectiveness and precision offered by CTCs in the detection of cancer
  • The early detection segment is projected to grow at the fastest CAGR over the forecast period, owing to the increasing adoption of liquid biopsy in early diagnosis of cancer and the rising need to provide effective treatment
  • Treatment selection was the highest revenue-generating segment in 2021 owing to the availability of a high number of products that aid treatment selection
  • Asia Pacific is expected to witness the fastest growth during the forecast period owing to increasing prevalence, improving healthcare infrastructure, and growing population

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
    • 1.1.1 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 Secondary Sources
    • 1.3.3 Primary Research
    • 1.3.4 Details Of Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis
      • 1.6.1.1 Approach 1: Commodity Flow Approach
      • 1.6.1.2 Approach 2: Country - Wise Market Estimation Using Bottom - Up Approach
  • 1.7 Global Market: Cagr Calculation
  • 1.8 Research Assumptions
  • 1.9 List Of Secondary Sources
  • 1.10 List Of Primary Sources
  • 1.11 Objectives
    • 1.11.1 Objective 1:
    • 1.11.2 Objective 2:
  • 1.12 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Breast Cancer Liquid Biopsy Market Variables, Trends, & Scope

  • 3.1 Breast Cancer Liquid Biopsy Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook - In Vitro Diagnostics (Ivd) Market
  • 3.2 Penetration And Growth Prospect Mapping
  • 3.3 Market Dynamics
  • 3.4 Market Driver Analysis
    • 3.4.1 Increasing Prevalence Of Breast Cancer
    • 3.4.2 Increasing Adoption Of Liquid Biopsies In Cancer Diagnosis
    • 3.4.3 Need To Provide Early Diagnosis And Treatment
  • 3.5 Market Restraint Analysis
    • 3.5.1 High Cost Associated With Breast Cancer Liquid Biopsy Tests
    • 3.5.2 Regulatory & Reimbursement Hurdles
  • 3.6 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
  • 3.7 Porter's Five Forces Analysis

Chapter 4 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Circulating Biomarkers, 2018 - 2030 (USD Million)

  • 4.1 Breast Cancer Liquid Biopsy Market: Circulating Biomarkers Movement Analysis
    • 4.1.1 Circulating Tumor Cells (Ctcs)
      • 4.1.1.1 Circulating Tumor Cells (Ctcs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.1.2 Circulating Cell - Free Dna (Cfdna)
      • 4.1.2.1 Circulating Cell - Free Dna (Cfdna) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.1.3 Extracellular Vesicles (Evs)
      • 4.1.3.1 Extracellular Vesicles (Evs) Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 4.1.4 Other Circulating Biomarkers
      • 4.1.4.1 Other Circulating Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5 Breast Cancer Liquid Biopsy Market - Segment Analysis, By Application, 2018 - 2030 (USD Million)

  • 5.1 Breast Cancer Liquid Biopsy Market: Application Movement Analysis
    • 5.1.1 Early Detection/Screening
      • 5.1.1.1 Early Detection/Screening Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.2 Diagnosis
      • 5.1.2.1 Diagnosis Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.3 Treatment Selection
      • 5.1.3.1 Treatment Selection Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 5.1.4 Monitoring
      • 5.1.4.1 Monitoring Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6 Breast Cancer Liquid Biopsy Market - Segment Analysis, by Region, 2018 - 2030 (USD Million)

  • 6.1 Breast Cancer Liquid Biopsy Market: Regional Movement Analysis
  • 6.2 North America
    • 6.2.1 North America Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.2 U.S.
      • 6.2.2.1 U.S. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.2.3 Canada
      • 6.2.3.1 Canada Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.3 Europe
    • 6.3.1 Europe Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.2 U.K.
      • 6.3.2.1 U.K. Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.3 Germany
      • 6.3.3.1 Germany Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.4 France
      • 6.3.4.1 France Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.3.5 Italy
      • 6.3.5.1 Italy Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.3.6 Spain
      • 6.3.6.1 Spain Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
  • 6.4 Asia Pacific
    • 6.4.1 Asia Pacific Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.2 Japan
      • 6.4.2.1 Japan Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.3 China
      • 6.4.3.1 China Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.4 India
      • 6.4.4.1 India Market Estimates And Forecast, 2018 - 2030 (USD Million)
    • 6.4.4 Australia
      • 6.4.4.1 Australia Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.4.5 South Korea
      • 6.4.5.1 South Korea Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
  • 6.5 Latin America
    • 6.5.1 Latin America Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.5.2 Brazil
      • 6.5.2.1 Brazil Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.5.3 Mexico
      • 6.5.3.1 Mexico Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.5.3 Argentina
      • 6.5.4.1 Argentina Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
  • 6.6 Mea
    • 6.6.1 Mea Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.6.2 South Africa
      • 6.6.2.1 South Africa Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.6.3 Saudi Arabia
      • 6.6.3.1 Saudi Arabia Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)
    • 6.6.4 UAE
      • 6.6.4.1 UAE Breast Cancer Liquid Biopsy Market, 2018 - 2030 (USD Million)

Chapter 7 Breast Cancer Liquid Biopsy Market: Competitive Analysis

  • 7.1 Recent developments and impact analysis, by key market participants
    • 7.1.1 Ansoff Matrix
    • 7.1.2 Major Deals And Strategic Alliances Analysis
      • 7.1.2.1 Market Expansion
      • 7.1.2.2 Product Launch
      • 7.1.2.3 Acquisition
      • 7.1.2.4 Partnerships And Collaborations
  • 7.2 Company Categorization
    • 7.2.1 Innovators
    • 7.2.2 Market Leaders
  • 7.3 Vendor Landscape
    • 7.3.1 List Of Key Distributors And Channel Partners
    • 7.3.2 Key Customers
    • 7.3.3 Key Company Market Share Analysis, 2021
  • 7.4 Public Companies
    • 7.4.1 Company Market Position Analysis
    • 7.4.2 Heat Map Analysis
    • 7.4.3 Regional Network Map
    • 7.4.4 Competitive Dashboard Analysis
      • 7.4.4.1 Market Differentiators
  • 7.5 Private Companies
    • 7.5.1 List Of Key Emerging Companies
    • 7.5.2 Heat Map Analysis
    • 7.5.3 Regional Network Map

Chapter 8 Company Profiles

  • 8.1 The Menarini Group
    • 8.1.1 Company Overview
    • 8.1.2 Financial Performance
    • 8.1.3 Product Benchmarking
    • 8.1.4 Strategic Initiatives
  • 8.2 NeoGenomics Laboratories
    • 8.2.1 Company Overview
    • 8.2.2 Financial Performance
    • 8.2.3 Product Benchmarking
    • 8.2.4 Strategic Initiatives
  • 8.3 F. Hoffmann - La Roche Ltd.,
    • 8.3.1 Company Overview
    • 8.3.2 Financial Performance
    • 8.3.2 Product Benchmarking
    • 8.3.4 Strategic Initiatives
  • 8.4 Myriad Genetics, Inc.
    • 8.4.1 Company Overview
    • 8.4.2 Financial Performance
    • 8.4.3 Product Benchmarking
    • 8.4.4 Strategic Initiatives
  • 8.5 Thermo Fisher Scientific, Inc.
    • 8.5.1 Company Overview
    • 8.5.2 Financial Performance
    • 8.5.3 Product Benchmarking
    • 8.5.4 Strategic Initiatives
  • 8.6 QIAGEN
    • 8.6.1 Company Overview
    • 8.6.2 Financial Performance
    • 8.6.2 Product Benchmarking
    • 8.6.4 Strategic Initiatives
  • 8.7 Biocept, Inc.
    • 8.7.1 Company Overview
    • 8.7.2 Financial Performance
    • 8.7.3 Product Benchmarking
    • 8.7.4 Strategic Initiatives
  • 8.8 Sysmex Corporation
    • 8.8.1 Company Overview
    • 8.8.2 Financial Performance
    • 8.8.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.9 Fluxion Biosciences, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives
  • 8.10 Epic Sciences, Inc.
    • 8.9.1 Company Overview
    • 8.9.2 Financial Performance
    • 8.9.3 Product Benchmarking
    • 8.9.4 Strategic Initiatives

List of Tables

  • TABLE 1 List of secondary sources
  • TABLE 2 List of abbreviations
  • TABLE 3 Regulatory framework
  • TABLE 4 Global breast cancer liquid biopsy market, by region, 2018 - 2030 (USD Million)
  • TABLE 5 Global breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 6 Global breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 7 North America breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 8 North America breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 9 North America breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 10 U.S. breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 11 U.S. breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 12 Canada breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 13 Canada breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 14 Europe breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 15 Europe breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 16 Europe breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 17 U.K. breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 18 U.K. breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 19 Germany breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 20 Germany breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 21 Spain breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 22 Spain breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 23 France breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 24 France breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 25 Italy breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 26 Italy breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 27 Asia Pacific breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 28 Asia Pacific breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 29 Asia Pacific breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 30 Japan breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 31 Japan breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 32 China breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 33 China breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 34 India market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 35 India breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 36 Australia market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 37 Australia breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 38 South Korea market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 39 South Korea breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 40 South Korea breast cancer liquid biopsy market, by product circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 41 Latin America breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 42 Latin America breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 43 Latin America breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 44 Brazil breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 45 Brazil breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 46 Mexico breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 47 Mexico breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 48 Argentina breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 49 Argentina breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 50 MEA breast cancer liquid biopsy market, by country, 2018 - 2030 (USD Million)
  • TABLE 51 MEA breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 52 MEA breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 53 South Africa breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 54 South Africa breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 55 Saudi Arabia breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 56 Saudi Arabia breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)
  • TABLE 57 UAE breast cancer liquid biopsy market, by circulating biomarkers, 2018 - 2030 (USD Million)
  • TABLE 58 UAE breast cancer liquid biopsy market, by application, 2018 - 2030 (USD Million)

List of Figures

  • FIG. 1 Breast cancer liquid biopsy market segmentation
  • FIG. 2 Market research process
  • FIG. 3 Data triangulation techniques
  • FIG. 4 Primary research pattern
  • FIG. 5 Market research approaches
  • FIG. 6 Value - chain - based sizing & forecasting
  • FIG. 7 QFD modeling for market share assessment
  • FIG. 8 Market formulation & validation
  • FIG. 9 Breast cancer liquid biopsy market snapshot
  • FIG. 10 Penetration and growth prospect mapping for application, 2021 (USD Million)
  • FIG. 11 Market Dynamics
  • FIG. 12 Breast cancer liquid biopsy market driver impact
  • FIG. 13 Enzymes in the diagnosis of diseases
  • FIG. 14 Common applications of enzymes in pathology
  • FIG. 15 Breast cancer liquid biopsy market restraint impact
  • FIG. 16 Porter's five forces analysis
  • FIG. 17 Breast cancer liquid biopsy market: Circulating biomarkers outlook and key takeaways
  • FIG. 18 Circulating tumor Cells (CTCs) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 19 Circulating cell - free DNA (cfDNA) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 20 Extracellular Vesicles (EVs) market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 21 Others circulating biomarkers market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 22 Breast cancer liquid biopsy market: Application outlook and key takeaways
  • FIG. 23 Breast cancer liquid biopsy market: Application movement analysis
  • FIG. 24 Early detection/screening market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 25 Diagnosis market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 26 Treatment selection market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 27 Monitoring market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 28 Breast cancer liquid biopsy Market: Regional outlook and key takeaways
  • FIG. 29 Breast cancer liquid biopsy: Regional movement analysis
  • FIG. 30 North America
  • FIG. 31 North America. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 32 U.S.
  • FIG. 33 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 34 Canada
  • FIG. 35 Canada market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 36 Europe
  • FIG. 37 Europe market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 38 UK
  • FIG. 39 UK market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 40 Germany
  • FIG. 41 Germany market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 42 France
  • FIG. 43 France market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 44 Spain
  • FIG. 45 Spain market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 46 Italy
  • FIG. 47 Italy market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 48 Asia Pacific
  • FIG. 49 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 50 Japan
  • FIG. 51 Japan market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 52 China
  • FIG. 53 China. market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 54 India
  • FIG. 55 India market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 56 Australia
  • FIG. 57 Australia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 58 South Korea
  • FIG. 59 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 60 Latin America
  • FIG. 61 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 62 Brazil
  • FIG. 63 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 64 Mexico
  • FIG. 65 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 66 Argentina
  • FIG. 67 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 68 MEA
  • FIG. 69 MEA market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 70 South Africa
  • FIG. 71 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 72 Saudi Arabia
  • FIG. 73 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 74 UAE
  • FIG. 75 UAE market estimates and forecast, 2018 - 2030 (USD Million)
  • FIG. 76 Ansoff Matrix
  • FIG. 77 Strategy mapping
  • FIG. 78 Company market share analysis, 2021
  • FIG. 79 Heat map analysis
  • FIG. 80 Market differentiators
  • FIG. 81 Heat map analysis
  • FIG. 82 Regional network map